XML 9 R2.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 5,470 $ 7,935
Short-term investments 8,614 10,734
Prepaid clinical trial expenses 230 748
Other prepaid expenses and current assets 539 248
Total current assets 14,853 19,665
Property and equipment, net 49 119
Other assets 11 10
Total assets 14,913 19,794
Current liabilities:    
Accounts payable 1,133 1,998
Accrued clinical trial costs 1,523 820
Accrued expenses 1,025 866
Total current liabilities 3,681 3,684
Promissory note 8,900 0
Warrant liability 2,600 1,700
Total liabilities 15,181 5,384
Commitments and contingencies (Note 8)
Stockholders' equity (deficit)    
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2025 and December 31, 2024, respectively; no shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 0 0
Common stock, $0.0001 par value; 500,000,000 shares authorized at September 30, 2025 and December 31, 2024, respectively; 14,257,234 and 13,481,917, issued and outstanding at September 30, 2025 and December 31, 2024, respectively 4 4
Additional paid-in capital 178,293 174,166
Accumulated deficit (178,566) (159,764)
Accumulated other comprehensive income 1 4
Total stockholders' equity (deficit) (268) 14,410
Total liabilities and stockholders' equity $ 14,913 $ 19,794